trending Market Intelligence /marketintelligence/en/news-insights/trending/NuULKWBwMrKKRMKDAtqxCQ2 content esgSubNav
In This List

Starpharma drug shows superior anti-tumor activity in studies

Blog

Insight Weekly: M&A outlook; US community bank margins; green hydrogen players' EU expansion

Blog

Global M&A by the Numbers: Q2 2022

Blog

Insight Weekly: US bank M&A; low refinancing eases rates impact; Texas crypto mining booms

Blog

Infographic 2022 Top Tech Trends Shaping Corporations


Starpharma drug shows superior anti-tumor activity in studies

Starpharma Holdings Ltd.'s DEP irinotecan showed significantly better anti-tumor activity and increased survival rates in a variety of human colon cancer models.

The company was studying its drug against conventional irinotecan in a pre-clinical study. Irinotecan is a medication used to treat colon cancer and small cell lung cancer; it is sold under the Camptosar brand name.

DEP irinotecan is Starpharma's version of the conventional drug.

Based on the results, Starpharma is expediting the development of the drug and is scaling up the treatment for further pre-clinical studies prior to clinical trials.